Deep biological profiling based on human genome analysis is touted as an innovation tool for the next generation of treatments and diagnostic tools to improve health outcomes. To that end, a partnership between Boston-based Berg and the Genomics England, a UK government-led organization, has its sights set on sequencing 100,000 genomes.
Focusing on whole genome sequences across cancer and rare diseases, Berg, a precision medicine biopharmaceutical company, will try to determine the best ways to collaborate with clinicians and researchers to realize the potential benefit genomic sequencing data can hold for patients.
"Through our partnership with Genomics England, Berg will use artificial intelligence-based big data analytics to identify areas in the biology that have been affected by a diseased environment," Niven R. Narain, Berg's co-founder, president and CTO, said in a statement. "There will be novel data developed from this project and our goal is to apply Berg's technology and expertise in advancing the knowledge learned into an actionable benefit back to society. We are both humbled and excited to bring our technologies into the UK and greater European Union."
Berg is attempting to develop an analytical tool that will be used to process the data from its 100,000 Genomes Project. The company has also established genomic research collaborations with the Department of Defense, NIH and Harvard Medical School, among others.
More articles on genomics in healthcare:
Partners receives $12.3M for genomic medicine research
Mayo Clinic partners with private equity firms for genomics hub
10 of the most interesting infection control developments this year